Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19.

In late July, Vanderbilt University Medical Center will begin recruiting up to 1,000 volunteers in a late-stage study of an experimental COVID-19 vaccine developed by Moderna Inc. in collaboration with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

An experimental coronavirus vaccine stimulated robust immune responses against SARS-CoV-2, the virus that causes COVID-19, and raised no serious safety concerns in an early-stage clinical trial.

For the world’s web users, Vanderbilt University Medical Center is working with Google to address COVID-19 information gaps.

The IVY Research Network has completed initial studies evaluating the epidemiology of COVID-19 in health care workers and patients.

This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.

On March 27, Nashville resident Bill Boyce, 73, earned the unwelcome distinction of becoming the first patient intubated on Vanderbilt University Medical Center’s dedicated COVID-19 unit.